Biogen Idec Photos

Exterior RTP
Bird's Eye View
Interior RTP

+ Add Photo

Biogen Idec Reviews

3.9
267 Reviews
Rating Trends
Recommend to a friend
Approve of CEO
Biogen Idec CEO and Director George A. Scangos
George A. Scangos
152 Ratings

Biogen Idec Interviews

Interview Experience

Interview Experience

60%
25%
13%

Getting an Interview

Getting an Interview

37%
27%
13%

Interview Difficulty

3.0
Average

Interview Difficulty

Hard

Average

Easy
  1.  

    Area Business Manager Interview

    Anonymous Interview Candidate in Sydney
    Accepted Offer
    Positive Experience
    Average Interview
    Accepted Offer
    Positive Experience
    Average Interview

    Application

    I applied online – interviewed at Biogen Idec (Sydney) in November 2013.

    Interview

    3 stage interview process, experience and industry understanding seems mandatory for these roles. Went through normal type scenarios and how to overcome them. Questions and probes about career aspiriations in 2-5 years time. Experience in Neurology and MS specialty preferred. Line manager is 1st interview step , followed by meeting with Leadership team for final round interview. Process was not exhaustive and invasive.

    Interview Questions

    • Where do I think I will be in 5 years time.   1 Answer

Biogen Idec Awards and Accolades

Something missing? Add an award
Top Employer, Science Magazine, 2012
Top Employer, Science Magazine, 2011
Show More

Additional Info

Unlock Profile
Website www.biogenidec.com
Headquarters Cambridge, MA
Size 5000+ Employees
Founded 1978
Type Company - Public (BIIB)
Industry Biotech & Pharmaceuticals
Revenue $5 to $10 billion (AUD) per year
Competitors Unknown

With its pipeline full of biotech drugs, Biogen Idec aims to meet the unmet needs of patients around the world. The biotech giant is focused on developing treatments in the areas of immunology and neurology. Its product roster includes best-selling Avonex, a popular drug for the treatment of relapsing multiple sclerosis (MS); Tysabri, a drug treatment for MS and Crohn's disease (developed with Elan); Rituxan, a monoclonal antibody developed jointly with Genentech that treats non-Hodgkin's lymphoma and rheumatoid arthritis; and Fumaderm, a psoriasis drug marketed in... More

Work at Biogen Idec? Share Your Experiences

Biogen Idec

 
Click to Rate
or